Nuvalent to Participate in Upcoming March Investor Conferences
CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in fireside chats during the following March investor conferences:
TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 9:50 a.m. ET in Boston;
Leerink Global Healthcare Conference 2025 on Monday, March 10, 2025 at 10:40 a.m. ET in Miami, FL; and,
Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025 at 2:30 p.m. ET in Miami, FL.
Live webcasts will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentations.
About NuvalentNuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-upcoming-march-investor-conferences-302388052.html
SOURCE Nuvalent, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
16 minutes ago
- Business Insider
‘Nothing Lasts Forever,' Says Top Investor About Palantir Stock
Palantir (NASDAQ:PLTR) stock presents investors with quite a quandary. Confident Investing Starts Here: On the one hand, there is no denying that the company has delivered incredible growth over the past few years. Its revenues are skyrocketing, its margins are strong, and its list of customers continues to grow by leaps and bounds. Its share price has responded in kind, surging by over 466% over the past twelve months. And therein lies the rub, as PLTR is now trading at elevated multiples that are far and above the sector average. This leads to the question of whether all that company growth has led to enthusiasm that is a bit too optimistic. Top investor Riyado Sofian is decidedly on the fence, and is not sure which way the winds will blow. 'It's hard to decide whether to buy or sell — best to just hold it,' states the 5-star investor, who is in the top 3% of TipRanks' stock pros. Sofian outlines the bull case, describing a company that has introduced game-changing AI technology that sets the firm apart from its peers. Beyond the growing sales, profits, and customers, the investor also points out that revenues from Palantir's top 20 customers increased by 26% year-over-year, a strong indication of customer satisfaction. While the company continues to raise its guidance, it often succeeds in going well beyond these numbers, notes Sofian, and it has repeatedly 'destroyed its guidance' in previous quarters. In other words, more massive growth could be on the horizon for Palantir. 'All things considered, this is execution on an elite level — there's no denying it,' adds Sofian. And yet, judging by traditional metrics, the company is overvalued, the investor acknowledges, and its narrative as 'the most important AI company in the West' is what has powered its continuing ascent. For that reason, as long as the company's growth continues apace, PLTR should continue to rise as well. However, that is far from certain, and at a valuation of 100x its revenues, there is practically no room for error if the impressive rate starts to slow. To this point, Sofian reminds investors that nothing lasts forever. With neither a Buy nor a Sell looking particularly appealing, Sofian is splitting the difference and rating PLTR shares a Hold (i.e. Neutral). (To watch Sofian's track record, click here) That stance is echoed across Wall Street. Of the 18 analyst reviews on file, 11 say Hold, while just 3 recommend Buy and 4 suggest Sell, making PLTR a consensus Hold. The average 12-month price target sits at $101.06, implying a ~23% downside from current levels. (See PLTR stock forecast) To find good ideas for AI stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
28 minutes ago
- Yahoo
Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria
ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study BOSTON and LAUSANNE, Switzerland, June 10, 2025 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces the submission of a Clinical Trial Application (CTA) to Germany's Paul-Ehrlich-Institut (PEI) to initiate a Phase 1/1b study of ALY-301 in healthy volunteers and patients suffering from Cold Urticaria, a subtype of Chronic Inducible Urticaria (CIndU). Cold Urticaria is a chronic skin disease where red, itchy wheals or hives appear after the skin is exposed to cold temperatures. It is a well-established clinical model for mast cell-mediated diseases in general, and chronic spontaneous urticaria in particular. Current and emerging solutions do not address the significant unmet medical needs experienced by patients. In conjunction with limited treatment options, the Urticaria market is projected to reach multiple billions within the next ten years. ALY-301 is the first mast cell-selective c-Kit inhibitor to enter the clinic. It is a cis-targeting bispecific antibody binding c-Kit and CD-203c, allowing selective targeting and depletion of mast cells over other c-Kit positive cells. This differentiated profile of ALY-301 is expected to offer a significantly improved safety profile over conventional c-Kit targeting agents and enable safe, chronic dosing in multiple mast-cell dependent diseases such as Chronic Urticaria. The trial will evaluate the safety and efficacy of ALY-301 at multiple sites across Germany. This CTA submission is the first clinical program to emerge from Alys' Granular platform, which is focused on the precise targeting of mast cell biology through advanced antibody engineering. Professor Brian Kim, Sol and Clara Kest Professor of Dermatology and Vice Chair of Research at Icahn School of Medicine at Mount Sinai and Head of Alys Pharmaceuticals Scientific Advisory Board, said: "ALY-301 offers a truly differentiated approach. It is the only c-Kit antibody designed to target activated mast cells while avoiding off-target effects. Unleashing the proven efficacy of c-Kit inhibition on mast cells, while sparing all other cell-types that have been associated with significant side effects, should result in a transformational drug profile for ALY-301 and could have a revolutionary impact on Chronic Urticaria and several other allergic indications." Professor Martin Metz, Professor of Dermatology at the Institute of Allergology at the Charité – Universitätsmedizin Berlin & Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology and Principal Investigator for ALY-301, commented: "The concept behind ALY-301, to enable safe and effective chronic dosing of a c-Kit agent through mast-cell selectivity, has been strongly supported across all non-clinical studies. It is very exciting to start the clinical journey today, especially since this first clinical trial will yield clinical outcomes from Urticaria patients." Thibaud Portal, Co-Founder and Chief Operating Officer of Alys Pharmaceuticals, added: "Recently, there has been intense attention to solving Urticaria and other allergic diseases, with keen interest in c-Kit targeting. Data have demonstrated the remarkable potency of the mode of action, but indiscriminate c-Kit targeting has been coupled with chronic safety challenges. ALY-301 is a first-in-class approach that combines the power of c-Kit inhibition with selectivity and safety. With its expected safety margin and broad applicability across multiple diseases, this marks another pivotal moment for Alys in our journey to bring innovative treatments to patients." This study marks the second major clinical milestone for Alys Pharmaceuticals. The Alys pipeline includes a diverse portfolio of assets targeting unmet needs in indications such as atopic dermatitis, chronic spontaneous urticaria, vitiligo, and systemic mastocytosis. The Company remains on track to deliver multiple clinical Proof-of-Concept (POC) readouts by 2027. About Alys PharmaceuticalsAlys Pharmaceuticals, Inc. ("Alys") is a Boston and Lausanne-based cutting edge pure-play immuno-dermatology company. Alys is backed by international investment firm Medicxi with $100M financing. Alys has a world class leadership team that brings together experts across dermatology and advanced scientific fields, including co-founders John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Craig Mello (UMass Chan Medical School), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology). Alys is led by dermatology specialist, co-founder, and COO Thibaud Portal. Its pipeline includes programs targeting multiple dermatological indications, including atopic dermatitis, vitiligo, chronic urticaria, psoriasis and mastocytosis. The Company entered the clinic in Q1 2025 with the siRNA platform developed by its affiliate Aldena Therapeutics, which offers the potential for long-lasting treatments that could transform the dermatology treatment landscape and is now advancing its mastocyte-selective therapies developed by affiliate Granular Therapeutics. For further information, please visit View original content: SOURCE Alys Pharmaceuticals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
MIFB Partners with MalaysiaPCA to Launch Gastronomic Sensory Hub
KUALA LUMPUR, Malaysia, June 10, 2025 /PRNewswire/ -- Malaysia's most influential F&B trade fair, the Malaysian International Food & Beverage Trade Fair (MIFB), has announced a landmark collaboration with the Malaysian Professional Culinaire Association (MalaysiaPCA) for 2025. Setting a new benchmark for experiential trade engagement in Malaysia's F&B industry, this year's edition marks the launch of the Gastronomic Sensory Hub, an experiential zone where culinary innovation and strategic business matchmaking converge. Built in consultation with exhibitors and curated by chefs, the Hub reimagines the traditional trade floor by transforming it into a living kitchen theatre; where product sourcing meets gastronomy, and every dish tells a story of Malaysian excellence and global readiness. "Our collaboration with MIFB reflects a shared mission to elevate Malaysia's culinary excellence on the world stage," said Chef Soon Pau Voon, Secretary General of MalaysiaPCA. "Through the Gastronomic Sensory Hub, we aim to inspire, train, and showcase the next generation of culinary innovators and reinforce Malaysia's place as a rising force in global gastronomy." Organised by Constellar and set to take place from 30 July to 1 August 2025 at the Kuala Lumpur Convention Centre, MIFB 2025 will host over 500 exhibitors from more than 50 countries, and is expected to attract over 12,000 industry professionals. Set against the theme "Future-Ready F&B: Serving the Evolution of Trends," the fair comes at a time when Malaysian consumers are demanding healthier, tastier food with clearer sourcing and production details. MIFB is answering that call with immersive, trend-led experiences instead of static exhibition booths. Created with input from exhibitors and chefs, the Gastronomic Sensory Hub gives buyers something they rarely get on the trade floor: the chance to see, taste, and test ingredients under real conditions. It features: Live cooking demos using exhibitor products; Ingredient application tests for chefs and food service professionals; Pop-up fine dining experiences to showcase product storytelling; and Knowledge-sharing sessions with award-winning culinary teams "Beyond giving exhibitors a voice, it's also about giving buyers an experience they will remember," said Bruno Thong, Portfolio Director of MIFB. "We want to show buyers, from restaurateurs to grocers, how an ingredient performs on the plate, not just on paper. That's what makes the Gastronomic Sensory Hub a game changer." Malaysian Culinary Stars in the Spotlight The Hub will spotlight Malaysia's top culinary talents including: Chef Ikhwan A star of Malaysia's fine dining movement, Chef Ikhwan merges European technique with Malaysian soul. He led the team to a Silver medal at the IKA Culinary Olympics 2024 and a Gold at the FHA Culinary Challenge 2022. Now leading Daun & Co and serving as Sous Chef at Hotel Renaissance KL, he will be headlining live demonstrations throughout MIFB. MalaysiaPCA National Culinary Team Fresh off a Silver medal win at the FHA National Team Challenge 2025, the team features chefs from Taylor's University, Hilton KL, Le Meridien, APCA, MIB College, and more, all bringing cutting-edge creativity and world-class technical finesse to the stage. Whether you are a chef, manufacturer, distributor, or retailer, MIFB 2025 is where the next chapter of Malaysian F&B will be written, driven by a shared vision with MalaysiaPCA, innovative showcases from local brands, and a deep understanding of evolving customer expectations. MIFB 2025, organised by Constellar, is now open for exhibitor and buyer registration at About MIFB Organised by Constellar, the Malaysian International Food and Beverage Trade Fair (MIFB) stands as Malaysia's premier food and beverage trade event, dedicated to facilitating connections at every stage of the supply chain to connect, network, and collaborate from upstream to downstream solutions. As the name 'Malaysian International Food & Beverage Trade Fair' suggests, MIFB brings together international exhibitors to meet local industry players, creating invaluable opportunities for global exporters seeking to establish business connections within the broader Malaysian market. Through MIFB, international and local F&B players converge to explore innovative solutions and drive industry growth. About Constellar Constellar is Asia's preferred partner for convening businesses, curating ideas and creating opportunities for sustainable business growth and global impact. Based in Singapore with a regional footprint in Malaysia, we curate and develop influential trade and consumer events for key industries and sectors, connecting people, global marketplaces and networks for sustainable growth. We also manage the Singapore EXPO, Singapore's largest purpose-built venue for Meetings, Incentives, Conventions and Exhibitions (MICE). Our vision is to be a global leader made in Asia, activating impactful networks to enable cross-industry collaboration and innovation through our holistic portfolio of intellectual properties in the MICE industry. Visit for more information. View original content to download multimedia: SOURCE Constellar Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
